On Monday, Shares of Best Buy Co Inc (NYSE:BBY), gained 0.13% to $30.53

Consumers who scored some of the $26 billion in gift cards given this past holiday are in luck. Gift cards for consumer electronics were among the most popular gifts this year, and Best Buy is making it easy to transform them into the goodies of people’s dreams with great deals on top products. Shoppers can enjoy savings on popular tech, accessories and appliances 24/7 on BestBuy. com and when stores open at 10 a. m. Offers comprise up to 30 percent off select tech, plus up to 50 percent off clearance, open-box products and more. Select Apple products are also on sale, with

the lowest prices of the season on Apple Watch, iPad and MacBook. Best Buy Co., Inc. operates as a retailer of technology products, services, and solutions in the United States and internationally. Its stores offer consumer electronics comprising primarily of television and home theaters; digital cameras and camcorders; DVD and Blu-ray players; portable electronics, such as MP3 devices, headphones and speakers, car stereo, navigation and satellite radio; and related accessories. Shares of Mattel, Inc. (NASDAQ:MAT), declined -0.79% to $27.47, during its last trading session.

DHX Media Ltd. and Mattel, declared a new, long-term partnership for the development, production and distribution of a range of new, multi-platform content inspired by the celebrated Mattel properties Bob the Builder™, Fireman Sam™, Little People® and Polly Pocket™. “Recently’s declaration is a major step forward in our ongoing strategy to dramatically accelerate content creation and distribution on a global scale,” said Catherine Balsam-Schwaber , Chief Content Officer of Mattel. “As a recognized leader in kids and family entertainment, DHX is ideally suited to assist us maximize content creation and distribution across multiple channels and geographies. Importantly, this relationship also creates the potential for future content, licensing and franchise development collaborations between Mattel and DHX.” Under the terms of the partnership, Mattel and DHX Media will jointly fund, co-develop and co-produce new episodic, short-form, and long-form content for the Mattel properties, designed for a variety of traditional and digital platforms. With Mattel’s additional expertise in brand franchise administration, strategy and consumer product licensing, and with DHX’s strength in global content distribution and creation, the companies will drive new production and growth for select Mattel properties.

Mattel, Inc. designs, manufactures, and markets a range of toy products worldwide. The company operates in three segments: North America, International, and American Girl. It offers dolls and accessories, vehicles and play sets, and games and puzzles under the Mattel Girls & Boys brands, counting Barbie, Monster High, Disney Classics, Ever After High, Little Mommy, Polly Pocket, Hot Wheels, Matchbox, CARS, Disney Planes, BOOMco, Radica, Toy Story, Max Steel, WWE Wrestling, and Batman.

Finally, Stem Cells Inc (NASDAQ:STEM), ended its last trade with 4.80% gain, and closed at $0.461. Stem Cells, declared a planned realignment to fully focus the Company’s resources on its proprietary HuCNS-SC® platform technology for the treatment of chronic spinal cord injury (SCI). Evidence of efficacy from the Company’s ongoing clinical trials in chronic SCI offers therapeutic promise to restore lost function formerly considered unrecoverable. StemCells recently stated a pattern of improvements in both strength and motor function, six months post-transplant of its proprietary HuCNS-SC cells, in the first cohort of its Phase II Pathway™ Study in cervical spinal cord injury. These interim findings are especially compelling given that all patients were treated between 10 to 23 months post-injury. Spontaneous motor recovery is not predictable in SCI at this late stage after injury.

Moreover, the emerging Phase II data are compriseent with the evolution of positive outcomes seen in the Company’s previous Phase I/II study in thoracic SCI, in which measurable sensory gains were stated in the majority of patients, and two of the seven patients enrolled with complete injuries (AIS A) converted to incomplete injuries (AIS B). “The decision to prioritize our spinal cord injury program required some difficult choices, counting the suspension of the Company’s Phase II Radiant™ Study in geographic atrophy of age-related macular degeneration (GA-AMD) while we seek a partner to fund continued development in retinal disorders,” said StemCells’ CEO Martin McGlynn. “Given the strength of our clinical findings for the safety and preliminary efficacy of our HuCNS-SC platform technology in treating chronic spinal cord injury, we have decided that now is the time to narrow our focus. Our overall mission remains the same: to realize the full potential of cell-based therapeutics as a one-time intervention yielding a long-term benefit for millions of patients affected by intractable diseases and disorders of the central nervous system.

While our programs addressing neurodegenerative diseases and retinal disorders have also shown great promise, we have concluded that the most effective way to accomplish our objective is by concentrating our limited corporate resources on the program with which we are making the most rapid progress — chronic spinal cord injury.” Stem Cells, Inc., a biopharmaceutical company, researches, develops, and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development. It engages in clinical development of its platform technology, HuCNS-SC, a purified human neural stem cells used as a potential treatment for disorders of the central nervous system.

DISCLAIMER: This article is published by www. wsnewspublishers. com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article. All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision. Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements.

Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.